Gene therapy is a promising approach for treating various genetic disorders and diseases. A critical component of gene therapy is the production of viral vectors, which serve as delivery vehicles for therapeutic genes. Human Embryonic Kidney 293 (HEK293) cells have become a widely used platform for viral vector production due to their efficiency in transfection and ability to support viral replication. However, optimizing HEK293 cell cultures for large-scale production of viral vectors remains a challenge in making gene therapies more accessible and cost-effective.
This article summarizes key concepts discussed in a webinar by Rui de Paula, Scientist and Instructor at the Jefferson Institute for Bioprocessing (JIB), and Mike Lesch, Regional Sales Manager at INFORS HT. The webinar focused on the role of incubator flexibility in optimizing HEK293 cell cultures for gene therapy applications, particularly in transitioning from adherent to suspension culture systems.
View the article to access the full application note and on-demand webinar
This article summarizes key concepts discussed in a webinar by Rui de Paula, Scientist and Instructor at the Jefferson Institute for Bioprocessing (JIB), and Mike Lesch, Regional Sales Manager at INFORS HT. The webinar focused on the role of incubator flexibility in optimizing HEK293 cell cultures for gene therapy applications, particularly in transitioning from adherent to suspension culture systems.
View the article to access the full application note and on-demand webinar
